Nordic Nanovector ASA publishes the 2018 annual report
OSLO, Norway, April 3, 2019 / PRNewswire / – Nordic Nanovector ASA has printed its 2018 Annual Report, together with the 2018 Annual Accounts full with notes. This report is connected to this announcement and is on the market on the Nordic Nanovector ASA web site: www.nordicnanovector.com.
For extra data, contact:
Malene Brondberg, VP of Investor Relations and Company Communications
Cellphone: + 44-7561-431-762
Electronic mail: [email protected]
Worldwide media inquiries
Mark Swallow/David dible (Citigate Dewe Rogerson)
Tel: + 44-207-638-9571
Electronic mail: [email protected]
In regards to the nordic nanovector
Nordic Nanovector is dedicated to growing and delivering revolutionary therapies to sufferers to deal with main unmet medical wants and advance most cancers care. The corporate goals to turn into a pacesetter within the growth of focused therapies for hematologic cancers.
The scientific candidate for the Nordic Nanovector lead stage is Betalutin®, a brand new CD37-directed radioimmunotherapy designed to advance the remedy of non-Hodgkin's lymphoma (NHL). NHL is a sign with a major unmet medical want, which represents a rising market. USD 29 billion by 2026. Nordic Nanovector intends to retain the advertising and marketing rights and actively take part within the advertising and marketing of Betalutin® in the primary markets.
Extra data could be discovered at www.nordicnanovector.com
This press launch comprises sure forward-looking statements. These statements are based mostly in your administration and are topic to uncertainties and circumstances, they are going to be affected by the character of your corporation. Situation and outcomes of operations. The phrases "anticipates", "assumes", "believes", "can", "may", "estimates", "expects", "predicts", "intends", "can", "may", "plans", The phrases "ought to", "tasks", "targets", "will", "would" or "different", or "different", or "different", or "different" or "comparable" are used to determine statements to future. These forward-looking statements aren’t historic information. There are a selection of things that would trigger future outcomes and developments to be materially affected by these concerned within the forward-looking statements. Components that may trigger these variations embody, amongst others, the dangers related to the implementation of the Nordic Nanovector technique, the dangers and uncertainties related to the event and / or approval of Nordic Nanovector candidate merchandise, the continued scientific trial and future and the anticipated outcomes of the trial. the flexibility to market Betalutin®, technological modifications and new merchandise within the Nordic Nanovector market and potential business, the liberty of operation of Nordic Nanovector (affect patents) with respect to the merchandise it develops, the flexibility to develop new merchandise and enhance present merchandise, the affect of competitors, modifications within the normal financial system and circumstances of the business, and legislative, regulatory and political components. There could be no assure that these expectations are appropriate. Nordic Nanovector denies any obligation to replace or revise any forward-looking assertion, whether or not on account of new data, future occasions or in any other case.
This data is topic to part 5-12 of the Securities Buying and selling Act.
This data was introduced by Cision http://information.cision.com
The next information can be found to obtain:
SOURCE Nordic Nanovector